Cantillon: Shareholders at Elan must be nonplussed by the frantic claim and counterclaim

Elan dismisses claims by Jack Schuler whom it calls ‘disgruntled’ as Royalty challenges Takeover Panel ruling

Founded in 1996, it built a major business by procuring the rights to royalties of some of the major drugs in the market, including Humira, Januvia, Lyrica and Remicade

Revised bid still ‘grossly untervalues’ Tysabri drug, board says

Royalty Pharma last week increased hostile cash bid for Elan

Drugmaker seems a long way from the measured approach that has typified the tenure of Kelly Martin

Irish pharmaceutical company agrees to buy 21% of royalty Theravance receives from GSK

Royalty submits its $5.7 billion bid, standing by a reduced price